THE WORLD ANTI-DOPING CODE

INTERNATIONAL
STANDARD FOR
THERAPEUTICUSE EXEMPTIONSJanuary 2011

International Standard for Therapeutic Use Exemptions
The International Standard for Therapeutic Use Exemptions was first adopted in 2004
and became effective in 2005. The enclosed represents version 5.0 that incorporates
revisions to the International Standard for Therapeutic Use Exemptions that wereapproved by the World Anti-Doping Agency Executive Committee on 18 September
2010. The revised International Standard for Therapeutic Use Exemptions is effective
as of 1 January 2011.
Published on 1 October 2010 by:
World Anti-Doping Agency
Stock Exchange Tower
800 Place Victoria (Suite 1700)
PO Box 120
Montreal, Quebec,
Canada H4Z 1B7
URL: www.wada-ama.org
Tel:
Fax:
E-mail:+ 1 514 904 9232
+ 1 514 904 8650
info@wada-ama.org

International Standard for Therapeutic Use Exemptions
January 2011

2

PREAMBLE
The World Anti-Doping Code International Standard for Therapeutic Use Exemptions(TUE) is a Level 2 mandatory International Standard developed as part of the World
Anti-Doping Program.
The official text of the International Standard for TUE shall be maintained by WADA
and shall be published in English and French. In the event of any conflict between
the English and French versions, the English version shall prevail.
The International Standard for TUE (version 5.0) will come into effect on 1 January
2011.

International Standard for Therapeutic Use Exemptions
3
January 2010

TABLE OF CONTENTSPART ONE: INTRODUCTION, CODE PROVISIONS AND DEFINITIONS................... 5
1.0

Introduction and Scope.......................................................................... 5

2.0

Code Provisions .................................................................................... 6

3.0

Terms and Definitions ............................................................................ 8

PART TWO: STANDARDS FOR GRANTING THERAPEUTIC USE EXEMPTIONS ........ 12
4.0

Criteria for Granting a Therapeutic Use Exemption .................................. 12

5.0

Confidentiality of Information ............................................................... 13

6.0

Therapeutic Use Exemption Committees (TUECs) .................................... 14

7.0

Responsibilities of International Federations and National Anti-Doping
Organizations ..................................................................................... 14

8.0

TUE Application Process ....................................................................... 16

9.0

Declaration of Use ............................................................................... 17

10.0

Review of TUE Decisions by WADA ........................................................ 17

11.0

Previously Granted Abbreviated Therapeutic Use Exemptions (ATUEs) ....... 18

ANNEX 1 ..................................................................................................... 19

International Standard for Therapeutic Use Exemptions
4
January 2010

PART ONE: INTRODUCTION, CODE PROVISIONS AND
DEFINITIONS
1.0 Introduction and Scope
The purpose of the International Standard for Therapeutic Use Exemptions is to ensure thatthe process of granting therapeutic use exemptions is harmonized across sports and countries.
The Code permits Athletes to apply for therapeutic use exemptions (TUE) i.e. permission touse, for therapeutic purposes, substances or methods contained in the List of Prohibited
Substances or Methods where Use would otherwise be prohibited.
The International Standard for TUE includes criteria for granting a TUE, confidentiality of
information, the formation of Therapeutic Use Exemptions Committees and the TUE application
process.
This Standard applies to all Athletes as defined by and subject to the Code i.e. able-bodied
Athletes and Athletes with disabilities.
[Comment: This Standard will be applied according to an individual’s circumstances. For example, an
exemption that is appropriate for an Athlete with a disability may be inappropriate for other Athletes.]

The World Anti-Doping Program encompasses all of the elements needed in order to ensure
optimal harmonization and best practice in international and national anti-doping programs.
The main elements are: the Code (Level 1), International Standards (Level 2), and Models ofBest Practice (Level 3).
In the introduction to the Code, the purpose and implementation of the International
Standards are summarized as follows:“International Standards for different technical and operational areas within the anti-doping
program will be developed in consultation with the Signatories and governments and approved
by WADA. The purpose of the International Standards is harmonization among Anti-Doping
Organizations responsible for specific technical and operational parts of the anti-doping
programs. Adherence to the International Standards is mandatory for compliance with the Code.
The International Standards may be revised from time to time by the WADA Executive
Committee after reasonable consultation with the Signatories and governments. Unless provided
otherwise in the Code, International Standards and all revisions shall become effective on thedate specified in the International Standard or revision.”

Compliance with an International Standard (as opposed to another alternative standard,practice or procedure) shall be sufficient to conclude that the procedures covered by theInternational Standard were performed properly.
Definitions specified in the Code are written in italics. Additional definitions specific to theInternational Standard for TUE are underlined.

International Standard for Therapeutic Use Exemptions
5
January 2010

2.0 Code Provisions
The following articles in the 2009 Code are directly relevant to the International Standard for
TUE:
Code Article 4.4 Therapeutic Use
WADA has adopted an International Standard for the process of granting therapeuticuse exemptions.
Each International Federation shall ensure, for International-Level Athletes or any otherAthlete who is entered in an International Event, that a process is in place whereby
Athletes with documented medical conditions requiring the Use of a Prohibited
Substance or a Prohibited Method may request a therapeutic use exemption. Athletes
who have been identified as included in their International Federation’s Registered
Testing Pool may only obtain therapeutic use exemptions in accordance with the rules of
their International Federation. Each International Federation shall publish a list of thoseInternational Events for which a therapeutic use exemption from the International
Federation is required. Each National Anti-Doping Organization shall ensure, for all
Athletes within its jurisdiction that have not been included in an International Federation
Registered Testing Pool, that a process is in place whereby Athletes with documented
medical conditions requiring the Use of a Prohibited Substance or a Prohibited Method
may request a therapeutic use exemption. Such requests shall be evaluated inaccordance with the International Standard for Therapeutic Use Exemptions.
International Federations and National Anti-Doping Organizations shall promptly report
to WADA through ADAMS the granting of any therapeutic use exemption except as
regards national-level Athletes who are not included in the National Anti-Doping
Organization’s Registered Testing Pool.
WADA, on its own initiative, may review at any time the granting of a therapeutic use
exemption to any International-Level Athlete or national-level Athlete who is included in
his or her National Anti-Doping Organization’s Registered Testing Pool. Further, upon
the request of any such Athlete who has been denied a therapeutic use exemption,
WADA may review such denial. If WADA determines that such granting or denial of atherapeutic use exemption did not comply with the International Standard for
Therapeutic Use Exemptions, WADA may reverse the decision.
If, contrary to the requirement of this Article, an International Federation does not havea process in place where Athletes may request therapeutic use exemptions, anInternational-Level Athlete may request WADA to review the application as if it had
been denied.
Presence of a Prohibited Substance or its Metabolites or Markers (Article 2.1), Use or
Attempted Use of a Prohibited Substance or a Prohibited Method (Article 2.2),
Possession of Prohibited Substances and Prohibited Methods (Article 2.6) or
Administration or Attempted Administration of a Prohibited Substance or Prohibited
Method (Article 2.8) consistent with the provisions of an applicable therapeutic use
exemption issued pursuant to the International Standard for Therapeutic Use
Exemptions shall not be considered an anti-doping rule violation.
International Standard for Therapeutic Use Exemptions
6
January 2010

Code Article 13.4
Use Exemption

Appeals from Decisions Granting or Denying a Therapeutic

Decisions by WADA reversing the grant or denial of a therapeutic use exemption may be
appealed exclusively to CAS by the Athlete or the Anti-Doping Organization whose
decision was reversed. Decisions by Anti-Doping Organizations other than WADA
denying therapeutic use exemptions, which are not reversed by WADA, may be
appealed by International-Level Athletes to CAS and by other Athletes to the nationallevel reviewing body described in Article 13.2.2. If the national-level reviewing bodyreverses the decision to deny a therapeutic use exemption, that decision may be
appealed to CAS by WADA.
When an Anti-Doping Organization fails to take action on a properly submitted
therapeutic use exemption application within a reasonable time, the Anti-Doping
Organization’s failure to decide may be considered a denial for purposes of the appeal
rights provided in this Article.
Code Article 14.5

Doping Control Information Clearinghouse

WADA shall act as a central clearinghouse for Doping Control Testing data and resultsfor International-Level Athletes and national-level Athletes who have been included intheir National Anti-Doping Organization’s Registered Testing Pool. To facilitate
coordinated test distribution planning and to avoid unnecessary duplication in Testing by
the various Anti-Doping Organizations, each Anti-Doping Organization shall report all InCompetition and Out-of-Competition tests on such Athletes to the WADA clearinghouseas soon as possible after such tests have been conducted. This information will be madeaccessible to the Athlete, the Athlete’s National Federation, National Olympic Committeeor National Paralympic Committee, National Anti-Doping Organization, International
Federation, and the International Olympic Committee or International Paralympic
Committee.
To enable it to serve as a clearinghouse for Doping Control Testing data, WADA has
developed a database management tool, ADAMS, that reflects emerging data privacy
principles. In particular, WADA has developed ADAMS to be consistent with data privacy
statutes and norms applicable to WADA and other organizations using ADAMS.
Private information regarding an Athlete, Athlete Support Personnel, or others involvedin anti-doping activities shall be maintained by WADA, which is supervised by Canadianprivacy authorities, in strict confidence and in accordance with the International
Standard for the protection of privacy. WADA shall, at least annually, publish statisticalreports summarizing the information that it receives, ensuring at all times that theprivacy of Athletes is fully respected and make itself available for discussions withnational and regional data privacy authorities.

International Standard for Therapeutic Use Exemptions
7
January 2010

Code Article 15.4 Mutual Recognition
15.4.1 Subject to the right to appeal provided in Article 13, Testing, therapeutic use
exemptions and hearing results or other final adjudications of any Signatory which areconsistent with the Code and are within that Signatory’s authority, shall be recognized
and respected by all other Signatories.
[Comment to Article 15.4.1: There has in the past been some confusion in the interpretation of this
Article with regard to therapeutic use exemptions. Unless provided otherwise by the rules of anInternational Federation or an agreement with an International Federation, National Anti-Doping
Organizations do not have “authority” to grant therapeutic use exemptions to International-Level
Athletes.]

15.4.2 Signatories shall recognize the same actions of other bodies which have notaccepted the Code if the rules of those bodies are otherwise consistent with the Code.
[Comment to Article 15.4.2: Where the decision of a body that has not accepted the Code is in somerespects Code compliant and in other respects not Code compliant, Signatories should attempt to apply
the decision in harmony with the principles of the Code. For example, if in a process consistent with theCode a non-Signatory has found an Athlete to have committed an anti-doping rule violation on accountof the presence of a Prohibited Substance in his body but the period of Ineligibility applied is shorter
than the period provided for in the Code, then all Signatories should recognize the finding of an antidoping rule violation and the Athlete’s National Anti-Doping Organization should conduct a hearing
consistent with Article 8 to determine whether the longer period of Ineligibility provided in the Codeshould be imposed.]

3.0 Terms and Definitions
3.1

Defined Terms from the CodeADAMS: The Anti-Doping Administration and Management System is a Web-based databasemanagement tool for data entry, storage, sharing, and reporting designed to assist
stakeholders and WADA in their anti-doping operations in conjunction with data protection
legislation.
Adverse Analytical Finding: A report from a laboratory or other WADA-approved entity that,consistent with the International Standard for Laboratories and related Technical Documents,
identifies in a Sample the presence of a Prohibited Substance or its Metabolites or Markers(including elevated quantities of endogenous substances) or evidence of the Use of a
Prohibited Method.
Anti-Doping Organization: A Signatory that is responsible for adopting rules for initiating,
implementing or enforcing any part of the Doping Control process. This includes, for example,
the International Olympic Committee, the International Paralympic Committee, other Major
Event Organizations that conduct Testing at their Events, WADA, International Federations,and National Anti-Doping Organizations.
Athlete: Any Person who participates in sport at the international level (as defined by each
International Federation), the national level (as defined by each National Anti-Doping
Organization, including but not limited to those Persons in its Registered Testing Pool), andany other competitor in sport who is otherwise subject to the jurisdiction of any Signatory orInternational Standard for Therapeutic Use Exemptions
8
January 2010

other sports organization accepting the Code. All provisions of the Code, including, forexample, Testing and therapeutic use exemptions, shall be applied to international- andnational-level competitors. Some National Anti-Doping Organizations may elect to test andapply anti-doping rules to recreational-level or masters competitors who are not current or
potential national caliber competitors. National Anti-Doping Organizations are not required,however, to apply all aspects of the Code to such Persons. Specific national rules may beestablished for Doping Control for non-international-level or non-national-level competitors
without being in conflict with the Code. Thus, a country could elect to test recreational-levelcompetitors but not require therapeutic use exemptions or whereabouts information. In thesame manner, a Major Event Organization holding an Event only for masters-level competitors
could elect to test the competitors but not require advance therapeutic use exemptions or
whereabouts information. For purposes of Article 2.8 (Administration or Attempted
Administration) and for purposes of anti-doping information and education, any Person who
participates in sport under the authority of any Signatory, government, or other sports
organization accepting the Code is an Athlete.
[Comment: This definition makes it clear that all international- and national-caliber Athletes are subject
to the anti-doping rules of the Code, with the precise definitions of international- and national-level
sport to be set forth in the anti-doping rules of the International Federations and National Anti-Doping
Organizations, respectively. At the national level, anti-doping rules adopted pursuant to the Code shallapply, at a minimum, to all persons on national teams and all persons qualified to compete in any
national championship in any sport. That does not mean, however, that all such Athletes shall be
included in a National Anti-Doping Organization’s Registered Testing Pool. The definition also allows
each National Anti-Doping Organization, if it chooses to do so, to expand its anti-doping program
beyond national-caliber Athletes to competitors at lower levels of competition. Competitors at all levelsof competition should receive the benefit of anti-doping information and education.]

Code: The World Anti-Doping Code.
Competition: A single race, match, game or singular athletic contest. For example, abasketball game or the finals of the Olympic 100-meter race in athletics. For stage races andother athletic contests where prizes are awarded on a daily or other interim basis thedistinction between a Competition and an Event will be as provided in the rules of theapplicable International Federation.
Doping Control: All steps and processes from test distribution planning through to ultimate
disposition of any appeal including all steps and processes in between such as provision ofwhereabouts information, Sample collection and handling, laboratory analysis, therapeutic use
exemptions, results management and hearings.
Event: A series of individual Competitions conducted together under one ruling body (e.g., theOlympic Games, FINA World Championships, or Pan American Games).
Event Period: The time between the beginning and end of an Event, as established by theruling body of the Event.
In-Competition: Unless provided otherwise in the rules of an International Federation orother relevant Anti-Doping Organization, “In-Competition” means the period commencing
twelve hours before a Competition in which the Athlete is scheduled to participate through theend of such Competition and the Sample collection process related to such Competition.
International Standard for Therapeutic Use Exemptions
9
January 2010

International Event: An Event where the International Olympic Committee, the International
Paralympic Committee, an International Federation, a Major Event Organization, or anotherinternational sport organization is the ruling body for the Event or appoints the technicalofficials for the Event.
International-Level Athlete: Athletes designated by one or more International Federations
as being within the Registered Testing Pool for an International Federation.
International Standard: A standard adopted by WADA in support of the Code. Compliancewith an International Standard (as opposed to another alternative standard, practice orprocedure) shall be sufficient to conclude that the procedures addressed by the International
Standard were performed properly. International Standards shall include any TechnicalDocuments issued pursuant to the International Standard.
National Anti-Doping Organization: The entity(ies) designated by each country as
possessing the primary authority and responsibility to adopt and implement anti-doping rules,
direct the collection of Samples, the management of test results, and the conduct of hearings,
all at the national level. This includes an entity which may be designated by multiple countries
to serve as regional Anti-Doping Organization for such countries. If this designation has notbeen made by the competent public authority(ies), the entity shall be the country’s National
Olympic Committee or its designee.
National Event: A sport Event involving international- or national-level Athletes that is not anInternational Event.
Out-of-Competition: Any Doping Control which is not In-Competition.
Possession: The actual, physical Possession, or the constructive Possession (which shall befound only if the Person has exclusive control over the Prohibited Substance or Prohibited
Method or the premises in which a Prohibited Substance or Prohibited Method exists);
provided, however, that if the Person does not have exclusive control over the Prohibited
Substance or Prohibited Method or the premises in which a Prohibited Substance or Prohibited
Method exists, constructive Possession shall only be found if the Person knew about thepresence of the Prohibited Substance or Prohibited Method and intended to exercise control
over it. Provided, however, there shall be no anti-doping rule violation based solely on
Possession if, prior to receiving notification of any kind that the Person has committed an antidoping rule violation, the Person has taken concrete action demonstrating that the Person
never intended to have Possession and has renounced Possession by explicitly declaring it toan Anti-Doping Organization. Notwithstanding anything to the contrary in this definition, thepurchase (including by any electronic or other means) of a Prohibited Substance or Prohibited
Method constitutes Possession by the Person who makes the purchase.
[Comment to Possession: Under this definition, steroids found in an Athlete's car would constitute a
violation unless the Athlete establishes that someone else used the car; in that event, the Anti-Doping
Organization shall establish that, even though the Athlete did not have exclusive control over the car,the Athlete knew about the steroids and intended to have control over the steroids. Similarly, in theexample of steroids found in a home medicine cabinet under the joint control of an Athlete and spouse,
the Anti-Doping Organization shall establish that the Athlete knew the steroids were in the cabinet andthat the Athlete intended to exercise control over the steroids.]APP

Definitions
Prohibited List: The List identifying the Prohibited Substances and Prohibited Methods.
International Standard for Therapeutic Use Exemptions
10
January 2010

Prohibited Method: Any method so described on the Prohibited List.
Prohibited Substance: Any substance so described on the Prohibited List.
Registered Testing Pool: The pool of top-level Athletes established separately by each
International Federation and National Anti-Doping Organization who are subject to both InCompetition and Out-of-Competition Testing as part of that International Federation’s or
National Anti-Doping Organization’s test distribution plan. Each International Federation shall
publish a list which identifies those Athletes included in its Registered Testing Pool either byname or by clearly defined, specific criteria.
Signatories: Those entities signing the Code and agreeing to comply with the Code, including
the International Olympic Committee, International Federations, International Paralympic
Committee, National Olympic Committees, National Paralympic Committees, Major Event
Organizations, National Anti-Doping Organizations, and WADA.
Testing: The parts of the Doping Control process involving test distribution planning, Sample
collection, Sample handling, and Sample transport to the laboratory.
Use: The utilization, application, ingestion, injection or consumption by any means
whatsoever of any Prohibited Substance or Prohibited Method.
WADA: The World Anti-Doping Agency.
3.2

Defined Terms from the International Standard for TUE

Personal Information: As defined in the International Standard for the Protection of Privacy
and Personal Information, information, including without limitation sensitive Personal
Information, relating to an identified or identifiable Participant or relating to other Persons
whose information is processed solely in the context of an Anti-Doping Organization’s antidoping activities.
[Comment: It is understood that Personal Information includes, but is not limited to, information
relating to an Athlete’s contact details and sporting affiliations, Whereabouts, designated therapeuticuse exemptions (if any), anti-doping test results, and results management (including disciplinary
hearings, appeals and sanctions). Personal Information also includes personal details and contact
information relating to other Persons, such as medical professionals and other Persons working with,treating or assisting an Athlete in the context of anti-doping activities.]

Therapeutic: Of or relating to the treatment of a medical condition by remedial agents or
methods; or providing or assisting in a cure.
TUE: Therapeutic Use Exemption approved by a Therapeutic Use Exemption Committee basedon a documented medical file and obtained before Use or Possession of, a substance or
method that would otherwise be prohibited by the Code.
TUEC: Therapeutic Use Exemption Committee is the panel established by the relevant AntiDoping Organization.
WADA TUEC: WADA Therapeutic Use Exemption Committee is the panel established by
WADA.
International Standard for Therapeutic Use Exemptions
11
January 2010

PART TWO: STANDARDS FOR GRANTINGTHERAPEUTIC USE EXEMPTIONS
4.0 Criteria for Granting a Therapeutic Use Exemption
A Therapeutic Use Exemption (TUE) may be granted to an Athlete permitting the Use of a
Prohibited Substance or Prohibited Method. An application for a TUE will be reviewed by a
Therapeutic Use Exemption Committee (TUEC). The TUEC will be appointed by an Anti-Doping
Organization.
4.1

4.2

A TUE will be granted only in strict accordance with the following criteria:a.

The Athlete would experience a significant impairment to health if the Prohibited
Substance or Prohibited Method were to be withheld in the course of treating anacute or chronic medical condition.

b.

The Therapeutic Use of the Prohibited Substance or Prohibited Method would
produce no additional enhancement of performance other than that which might
be anticipated by a return to a state of normal health following the treatment of alegitimate medical condition. The Use of any Prohibited Substance or Prohibited
Method to increase “low-normal” levels of any endogenous hormone is notconsidered an acceptable Therapeutic intervention.

c.

There is no reasonable Therapeutic alternative to the Use of the otherwise
Prohibited Substance or Prohibited Method.

d.

The necessity for the Use of the otherwise Prohibited Substance or Prohibited
Method cannot be a consequence, wholly or in part, of the prior Use, without a
TUE, of a substance or method which was prohibited at the time of Use.

The TUE will be cancelled, if:a.

The Athlete does not promptly comply with any requirements or conditions
imposed by the Anti-Doping Organization granting the exemption.

b.

The term for which the TUE was granted has expired.

c.

The Athlete is advised that the TUE has been withdrawn by the Anti-Doping
Organization.

d.

A decision granting a TUE has been reversed by WADA or CAS.

[Comment: Each TUE will have a specified duration as decided upon by the TUEC. There may be cases
when a TUE has expired or has been withdrawn and the Prohibited Substance subject to the TUE is stillpresent in the Athlete’s body. In such cases, the Anti-Doping Organization conducting the initial review
of an Adverse Analytical Finding will consider whether the finding is consistent with expiry or withdrawalof the TUE.]

International Standard for Therapeutic Use Exemptions
12
January 2010

4.3 An application for a TUE will not be considered for retroactive approval except in cases
where:a.

Emergency treatment or treatment of an acute medical condition was necessary,orb.

Due to exceptional circumstances, there was insufficient time or opportunity for
an applicant to submit, or a TUEC to consider, an application prior to Doping
Control.

[Comment: Medical emergencies or acute medical situations requiring administration of an otherwise
Prohibited Substance or Prohibited Method before an application for a TUE can be made, areuncommon. Similarly, circumstances requiring expedited consideration of an application for a TUE due
to imminent competition are infrequent. Anti-Doping Organizations granting TUEs should have internal
procedures that permit such situations to be addressed.]

5.0 Confidentiality of Information
5.1 The collection, storage, processing, disclosure and retention of Personal Information in
the TUE process by Anti-Doping Organizations and WADA shall comply with the International
Standard for the Protection of Privacy and Personal Information.
5.2 An Athlete applying for a TUE shall provide written consent for the transmission of all
information pertaining to the application to members of all TUECs with authority under the
Code to review the file and, as required, other independent medical or scientific experts, andto all necessary staff involved in the management, review or appeal of TUEs, and WADA. The
applicant shall also provide written consent for the decision of the TUEC to be distributed toother relevant Anti-Doping Organizations and National Federations under the provisions of the
Code.
[Comment to 5.2: Prior to collecting Personal Information or obtaining consent from an Athlete, theAnti-Doping Organization shall communicate to the Athlete the information set forth in Article 7.1 of theInternational Standard for the Protection of Privacy and Personal Information.]

Should the assistance of external, independent experts be required, all details of theapplication will be circulated without identifying the Athlete concerned.
5.3 The members of the TUECs, independent experts and the staff of the Anti-Doping
Organization involved, will conduct all of their activities in strict confidence and will signconfidentiality agreements. In particular they will keep the following information confidential:a.

All medical information and data provided by the Athlete and physician(s)involved in the Athlete’s care.

b.

All details of the application including the name of the physician(s) involved in theprocess.

Should the Athlete wish to revoke the right of any TUEC to obtain any health information on
his/her behalf, the Athlete shall notify his/her medical practitioner in writing of the fact. As aconsequence of such a decision, the Athlete will not receive approval for a TUE or renewal ofan existing TUE.
International Standard for Therapeutic Use Exemptions
13
January 2010

5.4 Anti-Doping Organizations shall ensure that Personal Information obtained in the TUE
process is retained for a period of eight (8) years, and thereafter only for as long as necessary
to fulfill their obligations under the Code or where otherwise required by applicable law,regulation or compulsory legal process.

6.0 Therapeutic Use Exemption Committees (TUECs)
TUECs shall be constituted and act in accordance with the following guidelines:
6.1 TUECs should include at least three (3) physicians with experience in the care andtreatment of Athletes and a sound knowledge of clinical, sports and exercise medicine. In
order to ensure a level of independence of decisions, the majority of the members of any
TUEC should be free of conflicts of interest or political responsibility in the Anti-Doping
Organization. All members of a TUEC will sign a conflict of interest agreement. In applications
involving Athletes with disabilities, at least one TUEC member shall possess specific experience
with the care and treatment of Athletes with disabilities.
6.2 TUECs may seek whatever medical or scientific expertise they deem appropriate inreviewing the circumstances of any application for a TUE.
6.3 The WADA TUEC shall be composed following the criteria set out in Article 6.1. The
WADA TUEC is established to review the granting or denial of TUEs for International-Level
Athletes, Athletes entered in an International event as described under 7.1(b), or Athletes intheir National Anti-Doping Organization’s Registered Testing Pool as set forth in Article 4.4 of
the Code. In normal circumstances, the WADA TUEC shall render a decision within 30 days ofreceipt of all requested information.

7.0 Responsibilities of International Federations and National
Anti-Doping Organizations
7.1

Each International Federation shall:a.

Establish a TUEC as provided in Article 6.

b.

Publish a list of International Events for which a TUE granted pursuant to
the International Federation’s rules is required.

c.

Establish and publish a TUE process whereby any Athlete who is in theInternational Federation’s Registered Testing Pool or who is entered in an
International Event described in Article 7.1(b) may request a TUE for a
documented medical condition requiring the Use of a Prohibited Substanceor a Prohibited Method. Such TUE process shall comply with Article 4.4 of
the Code, this International Standard and the International Standard for
the Protection of Privacy and Personal Information.

d.

Publish any rule pursuant to which the International Federation will accept
TUEs granted by other Anti-Doping Organizations.

e.

Promptly report to WADA, through ADAMS, the granting of all TUEs,
including the approved substance or method, dosage, frequency and route

International Standard for Therapeutic Use Exemptions
14
January 2010

of administration, the duration of the TUE, any conditions imposed inconnection with the TUE, and its entire file.

7.2

f.

Promptly report the granting of a TUE to the relevant National Anti-Doping
Organization and National Federation.

g.

At WADA’s request, promptly provide its entire file on any TUE which has
been denied.

Each National Anti-Doping Organization shall:a.

Establish a TUEC as provided in Article 6.

b.

Identify and publish those categories of Athletes within its jurisdiction who
are required to obtain a TUE before Using a Prohibited Substance or a
Prohibited Method. At a minimum, this shall include all Athletes in the
National Anti-Doping Organization’s Registered Testing Pool and othernational-level Athletes as defined by the National Anti-Doping
Organization.

c.

Establish and publish a TUE process whereby any Athlete who is in the
National Anti-Doping Organization’s Registered Testing Pool or who is
described in 7.2(b) may request a TUE for a documented medical condition
requiring the Use of a Prohibited Substance or a Prohibited Method. Such
TUE process shall comply with Article 4.4 of the Code, this International
Standard and the International Standard for the Protection of Privacy andPersonal Information.

[Comment to 7.2(b): National Anti-Doping Organizations will not grant TUEs to Athletes in an
International Federation’s Registered Testing Pool except in those instances where the International
Federation’s rules recognize or give authority to National Anti-Doping Organizations to grant TUEs tosuch Athletes.]d.

Promptly report to WADA, through ADAMS, the granting of a TUE to any
Athlete in its Registered Testing Pool, and if applicable, to an Athlete in an
International Federation’s Registered Testing Pool or entered in an
International Event described in Article 7.1(b), including the approved
substance or method, dosage, frequency and route of administration, theduration of the TUE, any conditions imposed in connection with the TUE,
and its entire file.

e.

At WADA’s request, promptly provide its entire file on any TUE that has
been denied.

f.

Promptly report the granting of a TUE to the relevant National Federation
and International Federation where the rules of the International
Federation authorize NADO to grant TUEs to International-Level Athletes.

g.

Recognize TUEs granted by International Federations to Athletes in theInternational Federation’s Registered Testing Pool or entered in an
International Event as described under 7.1(b).

International Standard for Therapeutic Use Exemptions
15
January 2010

[As used in this Article 7, the term "publish" means: An Anti-Doping Organization shall
publish information by providing the information in a conspicuous place on its website and bysending the information to each National Federation which is subject to its rules.]

8.0 TUE Application Process
8.1 Unless the rules of their International Federation provide otherwise, the following
Athletes shall obtain a TUE from their International Federation:a.

Athletes in the International Federation’s Registered Testing Pool; andb.

Athletes participating in an International Event for which a TUE granted pursuant
to the International Federation’s rules is required.

8.2 Athletes not identified in Article 8.1 shall obtain a TUE from their National Anti-Doping
Organization.
[Comment to 8.1 and 8.2: Unless the rules of an International Federation provide otherwise, an Athlete
who already has a TUE from a National Anti-Doping Organization, but later becomes a member of theInternational Federation’s Registered Testing Pool or seeks to participate in an International Event which
the International Federation has identified as requiring an International Federation TUE, shall obtain a
new TUE from the International Federation.
The phrase “unless the rules of an International Federation provide otherwise” takes into account thefact that some International Federations, through their rules, are willing to recognize TUEs granted by
National Anti-Doping Organizations and do not require a new TUE application at the International
Federation level. Where such rules are in place, the Athlete should obtain a TUE from the Athlete’s
National Anti-Doping Organization.]

8.3 The Athlete should submit an application for a TUE no less than thirty (30) days before
he/she needs the approval (for instance, an Event).
8.4 A TUE will only be considered following the receipt of a completed application form thatshall include all relevant documents (see Annex 1 - TUE form). The application process shallbe dealt with in accordance with the principles of strict medical confidentiality.
8.5 The TUE application form(s), as set out in Annex 1, can be modified by Anti-Doping
Organizations to include additional requests for information, but no sections or items shall be
removed.
8.6 The TUE application form(s) may be translated into other language(s) by Anti-Doping
Organizations, but the English or French text shall remain on the application form(s).
8.7 The application shall identify the Athlete’s level of competition (e.g., International
Federation Registered Testing Pool), sport and, where appropriate, discipline and specificposition or role.
8.8 The application shall list any previous and/or current TUE requests, the body to whomthat request was made, the decision of that body, and the decisions of any other body on
review or appeal.
International Standard for Therapeutic Use Exemptions
16
January 2010

8.9 The application shall include a comprehensive medical history and the results of all
examinations, laboratory investigations and imaging studies relevant to the application. The
arguments related to the diagnosis and treatment, as well as duration of validity, should be
guided by the WADA “Medical Information to Support the Decisions of TUECs”.
8.10 Any additional relevant investigations, examinations or imaging studies requested by
the TUEC of the Anti-Doping Organization before approval will be undertaken at the expense of
the applicant.
[Comment to 8.10: In some cases, the applicant’s National Federation may elect to pay this expense.]

8.11 The application shall include a statement by an appropriately qualified physician
attesting to the necessity of the otherwise Prohibited Substance or Prohibited Method in thetreatment of the Athlete and describing why an alternative, permitted medication cannot, or
could not, be used in the treatment of this condition.
8.12 The substance or method, dose, frequency, route and duration of administration of theotherwise Prohibited Substance or Prohibited Method in question shall be specified. In case ofchange, a new application shall be submitted.
8.13 In normal circumstances, decisions of the TUEC should be completed within thirty (30)days of receipt of all relevant documentation and will be conveyed in writing to the Athlete by
the relevant Anti-Doping Organization. In case of a TUE application made in a reasonable time
limit prior to an Event the TUEC should use its best endeavors to complete the TUE process
before the start of the Event.
[Comment to 8.13: When an Anti-Doping Organization has failed to act on an Athlete’s TUE application
within a reasonable time, the Athlete may seek review by WADA as if the application was denied.]

9.0 Declaration of Use
9.1 There are no longer substances or methods on the Prohibited List that require a
Declaration of Use and therefore it is not necessary to file a Declaration of Use.

10.0 Review of TUE Decisions by WADA
10.1 The WADA TUEC may, at any time, review the grant of a TUE to an Athlete in theInternational Federation Registered Testing Pool, entered in an International Event as
described in 7.1(b), or a National Anti-Doping Organization Registered Testing Pool. In
addition to the information to be provided as set forth in Articles 7.1 and 7.2, the WADA TUEC
may also seek additional information from the Athlete, including further studies as described in
Article 8.10. If a decision granting a TUE is reversed by WADA upon review, the reversal shallnot apply retroactively and shall not disqualify the Athlete’s results during the period for which
the TUE had been granted and shall take effect no later than fourteen (14) days following
notification of the decision to the Athlete.
10.2 An Athlete in an International Federation Registered Testing Pool, entered in an
International Event as described in 7.1(b), or National Anti-Doping Organization Registered
Testing Pool may request that WADA review the denial of a TUE by submitting a written
request for review to WADA within twenty-one (21) days of the date of the denial. An Athlete
International Standard for Therapeutic Use Exemptions
17
January 2010

submitting such a request for review to WADA shall pay an application fee as established by
WADA and shall provide to the WADA TUEC copies of all information that the Athlete submitted
to the Anti-Doping Organization in connection with the TUE application. The WADA TUEC willassess the request based on the file that was available to the Anti-Doping Organization thathas denied the TUE but may, for the sake of clarification, seek additional information from theAthlete, including further studies as described in Article 8.10. Until the WADA review process
has been completed, the original TUE denial remains in effect. If WADA reverses the denial of
a TUE, the TUE shall immediately go into effect in accordance with the conditions set forth in
the WADA decision.
10.3 Decisions by WADA to affirm or reverse the TUE decisions of an Anti-Doping
Organization may be appealed to CAS as provided in Article 13 of the Code.

11.0 Previously Granted Abbreviated Therapeutic Use Exemptions(ATUEs)11.1 All previously granted ATUEs that have not already expired or been cancelled shall expire
on December 31, 2009.

International Standard for Therapeutic Use Exemptions
18
January 2010

ANNEX 1:
Therapeutic use exemption application form________________________________________________________________________________________
Identification of Anti-Doping Organization(Logo or Name of the ADO)

Application form
THERAPEUTIC USE EXEMPTIONSTUE

Please complete all sections in capital letters or typing
1.

Athlete Information

Surname: ___________________________ Given Names: ______________________________.
Female ⁪Male ⁪ Date of Birth (d/m/y)________________________

Address: __________________________________________________________________
City:_________________________ Country:____________________
Tel.: _____________________________(with international code)
Sport: ___________________

Postcode:_________

E-mail: ________________

Discipline/Position: ________________________

International or National Sport Organization: ________________________
Please mark the appropriate box:

□ I am part of an International Federation Registered Testing Pool
□ I am part of a National Anti-Doping Organization Testing Pool
□ I am participating in an International Federation
event for which a TUE granted pursuant to the1
International Federation’s rules is required - Name of the competition:_______________________□ None of the above

If athlete with disability, indicate disability: ___________________________________
1

Refer to your International Federation for the list of designated events

International Standard for Therapeutic Use Exemptions
19
January 2010

2.

Medical information

Diagnosis with sufficient medical information (see note 1):________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
If a permitted medication can be used to treat the medical condition, provide clinical justification for
the requested use of the prohibited medication________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

3.

Medication details

Prohibited substance(s):Generic name
1.

Dose

Route

Frequency

2.
3.

Intended duration of treatment:(Please tick appropriate box)

once only ⁪emergency ⁪or duration (week/month):____________________Have you submitted any previous TUE application:

yes ⁪

no ⁪

For which substance?
____________________________________________________________________
To
whom? ________________________________________ When? ________________________
Decision:

Approved ⁪Not approved ⁪International Standard for Therapeutic Use Exemptions
20
January 2010

4.

Medical practitioner’s declaration

I certify that the above-mentioned treatment is medically appropriate and that the use ofalternative medication not on the prohibited list would be unsatisfactory for this condition.

Name: _________________________________________________________________________
Medical specialty: ________________________________________________________________
Address: ____________________________________
Tel.: _______________________________________
Fax: _______________________________________
E-mail:______________________________________
Signature of Medical Practitioner:____________________________________

5.

Date: _________

Athlete’s declaration

I, ________________________________, certify that the information under 1. is accurate and that I
am requesting approval to use a Substance or Method from the WADA Prohibited List. I authorize
the release of personal medical information to the Anti-Doping Organization (ADO) as well as to
WADA authorized staff, to the WADA TUEC (Therapeutic Use Exemption Committee) and toother ADO TUECs and authorized staff that may have a right to this information under theprovisions of the Code.
I understand that my information will only be used for evaluating my TUE request and in the context
of possible anti-doping violation investigations and procedures. I understand that if I ever wish to(1) obtain more information about the use of my information; (2) exercise my right of access andcorrection or (3) revoke the right of these organizations to obtain my health information, I must
notify my medical practitioner and my ADO in writing of that fact. I understand and agree that it
may be necessary for TUE-related information submitted prior to revoking my consent to beretained for the sole purpose of establishing a possible anti-doping rule violation, where this isrequired by the Code.
I understand that if I believe that my personal information is not used in conformity with thisconsent and the International Standard for the Protection of Privacy and Personal Information I canfile a complaint to WADA or CAS.
Athlete’s signature: _________________________________

Date: _______________

Parent’s/Guardian’s signature: _________________________

Date: _______________(if the athlete is a minor or has a disability preventing him/her to sign this form, a parent or guardianshall sign together with or on behalf of the athlete)

International Standard for Therapeutic Use Exemptions
21
January 2010

6.

Note:

Note 1

Diagnosis
Evidence confirming the diagnosis shall be attached and forwarded with thisapplication. The medical evidence should include a comprehensive medical history
and the results of all relevant examinations, laboratory investigations and imaging
studies. Copies of the original reports or letters should be included when possible.
Evidence should be as objective as possible in the clinical circumstances and in thecase of non-demonstrable conditions independent supporting medical opinion willassist this application.

Incomplete Applications will be returned and will need to be resubmitted.
Please submit the completed form to the ADO and keep a copy for your records.

International Standard for Therapeutic Use Exemptions
22
January 2010